U.S. payers and CGP: Equip your lab for reimbursement of CGP with TSO Comprehensive

TruSight™ Oncology Comprehensive (TSO Comprehensive) is the first U.S. FDA-approved, distributable comprehensive genomic profiling (CGP) kit with pan-cancer companion diagnostic (CDx) claims, across solid malignant neoplasms, conveys a distinct clinical utility that payers appreciate.

This webinar will highlight how your lab can navigate TSO Comprehensive reimbursement by engaging with your payers, which tools to use and information to highlight during the billing processes. A regional laboratory serving a wide network across 7 states will share its experience navigating CGP RUO reimbursement, providing rapid access to CGP results for their oncologist through systematic lab-initiated testing and how TSO Comprehensive could positively impact their bottom line.

Learning objectives
•    Learn about TSO Comprehensive unique value proposition for U.S. payers
•    Equip your lab to engage with your payers to maximize reimbursement of your CGP
•    Review a US regional lab experience in optimizing CGP reimbursement and implementing laboratory-initiated CGP testing to better serve its oncologists and patients

Fill out the form to access content

I consent to the eBook sponsor processing my personal information to contact me by email and/or phone for marketing purposes in accordance with their Privacy Policy. I understand I can withdraw my consent/unsubscribe from being contacted by the sponsor at any time by clicking here.

By submitting this form, you consent to the collection and sharing of your contact details so we can respond to your inquiry and send relevant updates from illumina, including information on products, services, and events. Your data will be processed in Canada and then securely transferred to illumina, which will manage your information and handle any opt-out or removal requests. For details on how your data is used and protected, please review our Terms of Use and our Privacy, Opt-out, and Information Removal policies below.